Le Lézard
Classified in: Health, Science and technology
Subject: FDA

FDA Approves First Companion Diagnostic Test to Simultaneously Screen for Multiple Non-Small Cell Lung Cancer Therapies



CARLSBAD, Calif., June 22, 2017 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific for the first next-generation sequencing (NGS)-based test  that simultaneously screens tumor samples for biomarkers associated with three FDA-approved therapies for non-small cell lung cancer (NSCLC). Lung cancer is the leading cause of cancer-related deaths in the U.S., with NSCLC accounting for 85 percent of all lung cancers.1

FDA approves the Oncomine Dx Target Test, the first companion diagnostic of its kind that simultaneously screens tumor samples for biomarkers associated with three approved targeted therapies. The test is designed to help oncologists expedite selection of a treatment plan for their patients in days instead of weeks.

The Oncomine Dx Target Test simultaneously evaluates 23 genes clinically associated with NSCLC. Following FDA approval, results from analysis of three of these genes can now be used to identify patients who may be eligible for treatment with one of the following: the combined therapy of Tafinlar® and Mekinist®, XALKORI®, or IRESSA®. With this test, physicians can now match patients to these therapies in days instead of several weeks, which it often takes when screening samples one biomarker at a time.

"For people battling non-small cell lung cancer, time is critical and days matter," said Joydeep Goswami, president of clinical next-generation sequencing and oncology at Thermo Fisher. "The Oncomine Dx Target Test rapidly guides oncologists toward the right targeted therapy, with the goal of improving patient outcomes and the cost-efficiency of treatments."

LabCorp's Diagnostics and Covance Businesses, NeoGenomics Laboratories, and Cancer Genetics, Inc., are among the first laboratories that will offer the Oncomine Dx Target Test as a service to oncologists. All tests will be run on Thermo Fisher's Ion PGM Dx System, which received FDA 510(k) clearance in parallel for use on formalin-fixed, paraffin-embedded (FFPE) tissue samples.

"This first iteration of the test is just the beginning since the diagnostic claims of the Oncomine Dx Target Test may be expanded in the future based on the existing panel," Goswami added. "Thermo Fisher has entered into discussions with several pharmaceutical companies looking to use the panel for FDA-approved targeted therapy applications beyond lung cancer. Expanding the range of clinically actionable information is part of the company's goal to help our customers advance precision medicine."

Thermo Fisher developed the Oncomine Dx Target Test in collaboration with Novartis and Pfizer. It is based on Thermo Fisher's Ion AmpliSeq technology, which enables screening of tumor samples for multiple genetic markers with 10 nanograms of nucleic acid. Returning results using such a small amount of FFPE material is a critical advantage of the test since samples from patients with NSCLC are often limited in quantity.

More information about the Oncomine Dx Target Test is available at www.thermofisher.com/oncomine-dxtarget.

Tafinlar® and Mekinist® are registered trademarks of Novartis; XALKORI® is a registered trademark of Pfizer; and IRESSA® is a registered trademark of AstraZeneca.

1.  Non?Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship; Julian R. Molina, MD, PhD, Ping Yang, MD, PhD, Stephen D. Cassivi, MD, Steven E. Schild, MD, and Alex A. Adjei, MD, PhD

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands ? Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services ? we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.

Media Contact Information:

Mauricio Minotta, Thermo Fisher Scientific
+1 760 929 2456
+1 760 805 5266 (mobile)
mauricio.minotta@thermofisher.com

or

Maurissa Messier, CG Life
+1 908 208 9254
mmessier@cglife.com  

SOURCE Thermo Fisher Scientific Inc.


These press releases may also interest you

at 14:15
AMSTERDAM, Oct. 21, 2017 /PRNewswire/ -- Undeveloped, the fastest growing domain marketplace, has announced to enable all market features of the domain industry on the blockchain. "Every single month 8 million new businesses get started that bump...

at 09:30
LOS ANGELES, Oct. 21, 2017 /PRNewswire-iReach/ -- Onlinecarinsuranceinfo.com has released a new blog post explaining the advantages of having high deductibles with an auto insurance plan. A collision auto insurance works based on premiums and...

at 08:55
LONDON, Oct. 21, 2017 /PRNewswire/ -- DOVU's token sale has ended. The company collected a total of 20,000 Ether (ETH), with a current value of $6.2 million. This puts the project in a strong position to move forwards to build and market its core...

at 08:00
LOS ANGELES, Oct. 21, 2017 /PRNewswire-iReach/ -- Auto-car-insurance4.info has released a new blog post explaining why safety devices can improve auto insurance premiums. Drivers should focus on the safety of their cars. A family vehicle with a...

20 oct 2017
DALLAS, Oct. 20, 2017 /PRNewswire/ -- Blockchain technology is getting a higher education. As the demand grows for faster payments, settlements, and reconciliations, the blockchain will be playing an integral part of these fast-paced technological...

20 oct 2017
NEW ORLEANS, Oct. 20, 2017 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 27, 2017 to file lead plaintiff applications in a...




News published on 22 june 2017 at 17:02 and distributed by: